Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Blood

Volumn 121, Issue 8, 2013, Pages 1296-1303

  Ghobrial, Irene M ^a   Campigotto, Federico ^b   Murphy, Timothy J ^c   Boswell, Erica N ^a   Banwait, Ranjit ^a   Azab, Feda ^a   Chuma, Stacey ^a   Kunsman, Janet ^a   Donovan, Amanda ^a   Masood, Farzana ^a   Warren, Diane ^a   Rodig, Scott ^d   Anderson, Kenneth C ^a   Richardson, Paul G ^a   Weller, Edie ^b   Matous, Jeffrey ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Rocky Mountain Laser Center   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PANOBINOSTAT;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; HUMAN; LEG EDEMA; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; XEROSTOMIA;

EID: 84874401753     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-439307     Document Type: Article

References (26)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18(1):214-226. (Pubitemid 30036355)
2. Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol. 2004;5(3):239-247.
3. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23(7):1564-1577.
4. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115. (Pubitemid 36506291)
5. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4(11):679-685.
6. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom's macroglobulinemia. Blood. 2009;113(18):4163-4170.
7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286-298. (Pubitemid 46439286)
8. Fraga MF, Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle. 2005;4(10):1377-1381. (Pubitemid 41437126)
9. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19-25. (Pubitemid 46776612)
10. Roccaro AM, Sacco A, Jia X, et al. microRNAdependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood. 2010;116(9):1506-1514.
11. Sacco A, Issa GC, Zhang Y, et al. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol. 2010;3:38.
12. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):121-126. (Pubitemid 36506293)
13. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6(5):380-383.
14. Issa GC, Ghobrial IM, Roccaro AM. Novel agents in Waldenstrom macroglobulinemia. Clin Investig (Lond). 2011;1(6):815-824.
15. Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010;51(10):1779-1792.
16. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood. 2009;114(12):2375-2385.
17. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27(1):120-126.
18. Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol. 2011;4(3):245-252.
19. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol. 2009;147(1):97-101.
20. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009;5(5):601-612.
21. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12(15):4628-4635. (Pubitemid 44297814)
22. Wolf JL, Siegel D, Goldschmidt H, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53(9):1820-1823.
23. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Therap. 2011;10(11):2034-2042.
24. Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:303-309.
25. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830-3835.
26. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1408-1414.